ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Health Technology

Terumo Corp.

Business Summary

Terumo Corp. engages in the manufacturing and sale of medical products and equipment. It operates through the following segments: Cardiac and Vascular Company, General Hospital Company, and Blood Management Company. The Cardiac and Vascular Company segment offers services and treatments including cardiac and vascular surgery and interventional therapies performed inside blood vessels. The General Hospital Company segment provides infusion and closed anticancer drug infusion systems, measuring devices system with communication functions, diabetes management, adhesion barrier, and peritoneal dialysis. The Blood Management Company segment offers a combination of apheresis collections, manual and automated whole blood processing, and pathogen reduction. The company was founded by Shibasaburo Kitasato on September 17, 1921 and is headquartered in Tokyo, Japan.

Financial Highlights

Mar 2022 JPYUSD
Revenue703,303M6,258.66M
Gross Profit348,746M3,103.47M
Operating income118,121M1,051.15M
Income before tax114,061M1,015.02M
Net income88,813M790.34M
EBITDA177,003M1,575.14M
Diluted EPS117.371.04
Dividends Per Share340.30
Total Assets1,473.69B12,141.65M
Total liabilities461,373M3,801.21M
Total equity1,012.31B8,340.37M
Operating cash flow141,467M1,258.90M
Currency in JPYCurrency in USD

Historical Data

 Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022
Revenue 587,775M 599,481M 628,897M 613,842M 703,303M
Gross Profit 305,629M 312,203M 325,045M 307,165M 348,746M
Operating income 106,970M 100,621M 108,789M 97,694M 118,121M
Income before tax 106,630M 102,709M 106,466M 97,776M 114,061M
Net income 91,295M 79,470M 85,210M 77,267M 88,813M
EBITDA 149,005M 144,656M 161,147M 151,626M 177,003M
Diluted EPS 121.03 104.96 112.61 102.10 117.37
Dividends Per Share 25 27 28 29 34
Total Assets 1,081.04B 1,120.79B 1,241.35B 1,351.19B 1,473.69B
Total liabilities 530,606M 422,674M 486,468M 494,530M 461,373M
Total equity 550,307M 698,034M 754,813M 856,662M 1,012.31B
Operating cash flow 114,562M 93,571M 117,479M 121,485M 141,467M
 Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022
Revenue 5,303.27M 5,405.85M 5,784.24M 5,787.82M 6,258.66M
Gross Profit 2,757.57M 2,815.31M 2,989.58M 2,896.21M 3,103.47M
Operating income 965.15M 907.35M 1,000.58M 921.14M 1,051.15M
Income before tax 962.08M 926.18M 979.21M 921.91M 1,015.02M
Net income 823.72M 716.62M 783.71M 728.53M 790.34M
EBITDA 1,344.41M 1,304.44M 1,482.14M 1,429.65M 1,575.14M
Diluted EPS 1.09 0.94 1.03 0.96 1.04
Dividends Per Share 0.22 0.24 0.25 0.27 0.30
Total Assets 10,164.97M 10,125.94M 11,498.81M 12,227.98M 12,141.65M
Total liabilities 4,989.24M 3,818.71M 4,506.21M 4,475.38M 3,801.21M
Total equity 5,174.48M 6,306.49M 6,991.92M 7,752.59M 8,340.37M
Operating cash flow 1,033.65M 843.78M 1,080.50M 1,145.46M 1,258.90M

Valuation Measures

Mar 2022
PER31.70
ROA6.28%
ROE9.50%
Operating margin16.79%
Profit margin12.62%

Key executives

  • President, CEO & Representative Director: Shinjiro Sato
  • Chief Financial & Accounting Officer: Naoki Muto
  • Chief Clinical & Regulatory Affairs Officer: Kazuhisa Senshu
  • Chief Information Officer & Executive Officer: Katsuya Takeuchi
  • Director, Head-Compliance & Legal Affairs: Shouji Hatano

Shareholders

  • Nomura Asset Management Co., Ltd. (8.0%)
  • Daiwa Asset Management Co. Ltd. (3.8%)
  • Nikko Asset Management Co., Ltd. (3.8%)
  • Dai-ichi Life Holdings, Inc. (3.6%)
  • Meiji Yasuda Life Insurance Co. (3.2%)
  • Asset Management One Co., Ltd. (3.1%)
  • Mitsubishi UFJ Financial Group, Inc. (2.7%)
  • BlackRock Fund Advisors (2.7%)
  • The Vanguard Group, Inc. (2.3%)
  • Mitsubishi UFJ Kokusai Asset Management Co., Ltd. (2.0%)

Contact Details

  • Website:http://www.terumo.co.jp
  • Address: 2-44-1 Hatagaya, Shibuya-Ku, Tokyo, 151-0072, Japan
  • Phone: +81.3.3374.8111

Related Companies

  • Terumo Corp. /Nutritional Food Business/
  • Terumo Yamaguchi Corp.
  • Terumo BCT Japan, Inc.
  • Terumo Singapore Pte Ltd. (Yangon Branch)
  • Wego Terumo (Weihai) Medical Products Co., Ltd.
  • Terumo Taiwan Medical Co., Ltd.
  • Terumo France SAS
  • Terumo Medical Canada, Inc.
  • Terumo Restricted Stock Compensation Plan
  • Terumo China Holdings Co. Ltd.
  • Essen Technology Pte Ltd.
  • QUIREM Medical BV
  • TP Estate, Inc.
  • Terumo BCT Venezuela CA
  • Terumo BCT Portugal Unipessoal Lda.
  • Terumo Russia LLC
  • Terumo BCT Biotechnologies LLC
  • Terumo Colombia Andina SAS
  • Terumo BCT Colombia SA
  • Terumo BCT Uruguay SA
  • Terumo BCT Peru SAC
  • Terumo Panama International, Inc.
  • Terumo Mauritius Holding Ltd.
  • Terumo India Pvt Ltd.
  • Terumo BCT (Hong Kong) Ltd.
  • Terumo Medical (Shanghai) Co., Ltd.
  • Terumo Vietnam Medical Equipment Co., Ltd.
  • MicroVention Europe SARL
  • PT Terumo Indonesia
  • Terumo Singapore Pte Ltd.

Competitors

  • Merit Medical Systems, Inc.
  • Fresenius SE & Co. KGaA
  • Koninklijke Philips N.V.
  • Haemonetics Corporation
  • Getinge AB Class B
  • Fresenius Medical Care AG & Co. KGaA
  • Cerus Corporation
  • Silk Road Medical, Inc.
  • Cardiovascular Systems, Inc.
  • APT Medical Inc. Class A
  • Artivion, Inc.
  • AngioDynamics, Inc.
  • Stryker Corporation
  • InspireMD, Inc.
  • BioCardia, Inc.
  • LivaNova Plc
  • Retractable Technologies, Inc.
  • LeMaitre Vascular, Inc.
  • Lombard Medical Inc
  • Inspira Technologies Oxy B.H.N. Ltd.
  • CollPlant Biotechnologies Ltd
  • ABIOMED, Inc.
  • CytoSorbents Corporation
  • Penumbra, Inc.
  • T&R Biofab Co., Ltd
  • Aziyo Biologics, Inc. Class A
  • Guerbet SA
  • Quoin Pharmaceuticals, Ltd. Sponsored ADR
  • EOFlow Co., Ltd.
  • Humacyte, Inc.
Last Updated on 29 Sep, 2022

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more